A Study of JZP150 in Adults With Posttraumatic Stress Disorder

• Status: Not yet recruiting
• Trial end date: 2023-06-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a 12-week, double-blind, placebo-controlled, randomized, parallel-group, multicenter study of the safety and efficacy of JZP150 in the treatment of adult participants with post-traumatic stress disorder (PTSD).

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Jazz Pharmaceuticals

Criteria

Inclusion Criteria:

• Participants aged 18 to 70 years

• Participants must be outpatients with a primary diagnosis of Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) defined PTSD confirmed by the clinical interview

• PTSD is primary diagnosis

Exclusion Criteria:

• Acute or unstable medical condition, behavioral or psychiatric disorder (other than PTSD)

• Suicidal behavior in the past 2 years or active suicidal ideation in the past 6 months

• Ongoing traumatic event or exposure to a traumatic event <3 months prior to Screening

• Index event > 12 years

• Index event is combat trauma